Marshall Wace
CSBR icon

Marshall Wace’s Champions Oncology CSBR Stock Holding History

Marshall Wace’s Portfolio CSBR Stock Details CSBR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-10,066
Closed -$99K – 1429
2019
Q1 		$99K Buy
+10,066
New +$100K ﹤0.01% 1435

Other funds holding CSBR

BPI
Battery Partners IX Boston, Massachusetts $22.4M AUM 27.71% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCM
Cadence Capital Management Boston, Massachusetts $415M AUM 11.01% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
PCM
Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Marshall Wace's CSBR Position: Q2 2019 in Review

Marshall Wace sold out of Champions Oncology (CSBR) in Q2 2019, closing a stake of 10,066 shares — an estimated $99K sold.

Marshall Wace first reported a position in CSBR in Q1 2019 and held it in 1 quarter. The position peaked at $99K in Q1 2019. 37 funds tracked by Wall St. Rank hold CSBR as of Q2 2019.

  • Marshall Wace reported no remaining Champions Oncology position as of Q2 2019 after selling out during the quarter.
  • Marshall Wace sold 10,066 Champions Oncology shares in Q2 2019, an estimated $99K.
  • Marshall Wace first reported a position in Champions Oncology in Q1 2019 and held it in 1 quarter.
  • Marshall Wace's Champions Oncology position peaked at $99K in Q1 2019.
  • 37 funds tracked by Wall St. Rank held Champions Oncology as of Q2 2019.

Based on Marshall Wace's 13F filing for Q2 2019, filed 14 Aug 2019.